TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04243148

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Home exercise program for 12 months.
Description: Physical exercise at home: At the beginning of the study, group sessions will be conducted with 5 patients of 1-hour duration, where they will be taught the individualized program according to their physical condition and they will be given the necessary material (pedaling, dumbbells and elastic bands) and paper support on the program, also using the Vivifrail method through infographics. The group session will be repeated every 3 months to check the compliance of the program by reviewing daily activity, evaluate possible problems and review the exercises. The program will consist of aerobic and anaerobic exercise by pedaling (cardiovascular resistance) and resistance exercises with dumbbells and elastic bands (muscular strength), flexibility training by stretching, and coordination and balance exercises. Patients will perform 3 sessions per week of 20-30 min. increasing progressively according to tolerance up to 45-60 min. each.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic: Vivomixx®
Description: Multispecies probiotic: Vivomixx® is a probiotic mixture of 8 bacterial strains:~Streptococcus thermophilus DSM 24731® / NCIMB 30438, Bifidobacterium breve DSM 24732® / NCIMB 30441, Bifidobacterium longum DSM 24736® / NCIMB 30435\*, Bifidobacterium infantis DSM 24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM 24735® / NCIMB 30442, Lactobacillus plantarum DSM 24730® / NCIMB 30437, Lactobacillus paracasei DSM 24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734® / NCIMB 30440\*\*~\* Re-classified as B. lactis \*\* Re-classified as L. helveticus The active agent will be supplied as an envelope of 4.4 g with a dose of 450x109 million live bacteria per envelope with maltose and silicon dioxide as excipients, administered 2 times/day throughout the study.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA)
Description: Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements (powder in 8:1:1 ratio in favor of L-leucine) 10 g 30-60 min. before the exercise session throughout the study, in order to enhance the effect of exercise on muscle mass and improve cognitive function. We have chosen this dose based on the literature data and the satisfactory results obtained with this dose in our previous study. BCAA supplements will be supplied by the Pharmacy Service of our center.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: No specific intervention.
Description: Follow up as a clinical practice
Study: NCT00650507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SHAM
Description: For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
Study: NCT01474109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: macitentan 3mg
Description: macitentan 3mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: macitentan 10mg
Description: macitentan 10mg tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo once daily
Study: NCT01429688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anplag
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
Study: NCT02539446

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: stable condition

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: unstable condition

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: attentional focus
Study: NCT02905812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RGI & Massage
Description: A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
Study: NCT03379935

Intervention type: PROCEDURE
Intervention: Type of radial head arthroplasty
Description: Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.

Intervention type: PROCEDURE
Intervention: Type of radial head arthroplasty
Description: Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.
Study: NCT00917865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti [18F]FACBC
Description: Anti\[18F\]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
Study: NCT04201041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pudendal nerve pulsed radiofrequency
Description: received pudendal nerve pulsed radiofrequency through trans-vaginal approach or trans-gluteal approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pudendal nerve pulsed radiofrequency
Description: received pudendal nerve pulsed radiofrequency through trans-vaginal approach or trans-gluteal approach
Study: NCT01501188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo kinesio taping
Description: Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
Study: NCT02323529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
Study: NCT00600548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine.
Description: Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate.
Description: Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine.
Description: Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate.
Description: Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
Study: NCT04705623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: Weekly 90 minute Iyengar Yoga classes taught y a professional instructor. Twice weekly 45 minute self practice of Iyengar Yoga at home by the participants
Study: NCT02627183

Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).

Intervention type: BEHAVIORAL
Intervention: Exercise training
Description: Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
Study: NCT00375453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH U04722
Study: NCT04408898

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADP-A2M4 in combination with pembrolizumab.
Description: Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced cells by a single intravenous infusion Repeat doses of pembrolizumab every 3 weeks. Dose: 200mg
Study: NCT02806557

Intervention type: DEVICE
Intervention: Home finger-prick capillary blood count monitoring
Description: A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.

Intervention type: DEVICE
Intervention: Home finger-prick capillary blood count monitoring
Description: A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.

Intervention type: DEVICE
Intervention: Home finger-prick capillary blood count monitoring
Description: A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
Study: NCT01490086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP5063
Description: daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP5063
Description: daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP5063
Description: daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: daily
Study: NCT03916835

Intervention type: DEVICE
Group type: OTHER
Intervention: Pain evaluation ( FLACC scale) before and during the cleaning care with and without music therapy.
Description: Each child will benefit two cleaning cares during hospitalization. One with music therapy and the other without music therapy.~Every time, the preparation will be the same with an equipment installation in order to keep comparability and blind.~Child will be videotaped without sound during the care. The order of music therapy intervention will be randomized.

Intervention type: DEVICE
Group type: OTHER
Intervention: Pain evaluation ( FLACC scale) before and during the cleaning care with and without music therapy.
Description: Each child will benefit two cleaning cares during hospitalization. One with music therapy and the other without music therapy.~Every time, the preparation will be the same with an equipment installation in order to keep comparability and blind.~Child will be videotaped without sound during the care. The order of music therapy intervention will be randomized.
Study: NCT01290133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW597599
Description: Single dose IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose IV infusion
Study: NCT03614442

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: slopped shoulder implant
Description: different implant design to enhance soft and hard tissue outcome
Study: NCT01429688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
Study: NCT03614442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: slopped shoulder implant
Description: different implant design to enhance soft and hard tissue outcome
Study: NCT03294681

Intervention type: DEVICE
Intervention: Objective measures with CSEP
Description: Objective measures to be conducted with Custom SoundTM EP 5 software and the CP900 series sound processor in CI532 and CI512 Cochlear Implant recipients
Study: NCT00353652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 irbsesartan (IR), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 irbsesartan (IR), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 irbsesartan (IR), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 irbsesartan (IR), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 irbsesartan (IR), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
Study: NCT00778427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride 1000 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin hydrochloride 1000 mg tablets
Study: NCT02172794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to salmeterol
Study: NCT02536170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine Loading Dose
Description: One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
Study: NCT03156114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Day 1 of 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Day 1 of 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Day 1 of 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Day 1 of 3 week cycle
Study: NCT03700177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Injection [Naropin]
Description: 30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine Injection [Naropin]
Description: 30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
Study: NCT02536170

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
Study: NCT01009788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: Capsules taken orally twice a day on days 1-7 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: capsules taken orally once a day on days 1 through 5 of a 28 day cycle
Study: NCT02969434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep assessment tools
Description: Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
Study: NCT02720016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT-Home Based (CBCT-HB)
Description: Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
Study: NCT03589274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-FS-CBT
Description: 12 manual-guided sessions of I-FS-CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G-FS-CBT
Description: 12 manual-guided sessions of G-FS-CBT
Study: NCT03159182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure garment and silicone insert
Description: Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure garment
Description: Custom made fabric pressure garment
Study: NCT02720016

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBCT-Office Based (CBCT-OB)
Description: Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Family Education (PFE)
Description: Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
Study: NCT02416362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration at 30 Hz
Description: During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration at 50 Hz
Description: During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
Study: NCT03355937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sperm Chip
Description: Sperm selection using by conventional or with sperm chip

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sperm Chip
Description: Sperm selection using by conventional or with sperm chip

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sperm Chip
Description: Sperm selection using by conventional or with sperm chip

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sperm Chip
Description: Sperm selection using by conventional or with sperm chip
Study: NCT01959737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin-to.skin-contact
Description: Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
Study: NCT01189435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
Study: NCT01770873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take Charge 2
Description: Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
Study: NCT01948284

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: half-maximal pressure
Description: the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maximal pressure
Description: The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction Unit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction Unit
Study: NCT02191709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan soft pastilles
Study: NCT00511524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW842166X
Description: GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [carbonyl-^11C]GW842166
Description: \[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.
Study: NCT01679080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: antiresorptive and calcium and vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: antiresorptive and calcium and vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: anabolic and calcium and vitamin D

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No active treatment
Description: Calcium and vitamin D